Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market

Peter Hansen/iStock via Getty Images Moderna’s ( NASDAQ: MRNA ) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer ( NYSE: PFE ) and GSK ( NYSE: GSK ), is shrinking.

Cambridge, Massachusetts-based Moderna ( NASDAQ: MRNA ), the last of the trio to report Q3 results, reported $10M.